你即將離開本站

並前往https://www.precisiononcologynews.com/cancer/turning-point-therapeutics-begins-study-repotrectinib-mekinist-kras-g12d-mutated-cancers

Turning Point Therapeutics Begins Study of Repotrectinib ...

... will evaluate Turning Point's investigational agent plus Novartis' MEK inhibitor in advanced solid tumors harboring KRAS G12D mutations.

確定！ 回上一頁

查詢 「KRAS G12D」的人也找了：

  1. KRAS G12D inhibitor
    2.
  2. kras基因
    3.
  3. Sotorasib
    4.
  4. kras是什麼
    5.
  5. KRAS G12C
    6.
  6. KRAS mutation
    7.
  7. KRAS G12D lung cancer
    8.
  8. kras突變
    9.